As of June 12, 2018 our Privacy Policy has been updated. For individuals in the European Union, CIL uses cookies on this website. Please review the new privacy statement to see how. By continuing to use this website you agree to us using cookies in accordance with our privacy statement. Click here for the new privacy statement..OK

Corporate Overview

July 2, 2020 – In the wake of Covid 19, CIL holds local food drive

CIL recognizes the high level of food insecurities due to COVID-19 and wanted to give to the surrounding communities in need.To help those facing food insecurity in the wake of the COVID-19 outbreak, CIL held a food and personal care item drive supporting the Lawrence YMCA Food Pantry, partner of the Merrimack Valley Food Bank, Inc.

June 10, 2020 – Cambridge Isotope Laboratories Signs Distribution Agreement with FB Reagents to Sell Deuterated Phospholipids and Detergents

Cambridge Isotope Labs (CIL) is proud to offer an assortment of deuterated phospholipids and detergents manufactured by FB Reagents, Ltd. These compounds are being used to solubilize isotopically labeled membrane proteins for high-field nuclear magnetic resonance (NMR) spectroscopy, and to study membrane structure by small-angle neutron scattering (SANS). FBR’s products expand significantly CIL’s current offering of deuterated lipids and detergents.

June 4, 2020 – CIL Aides COVID-19-Related Research at MIT with 13C6 Glucose

CIL is aiding COVID-19-related research currently being conducted in the laboratory of Dr. Mei Hong, a professor of chemistry at MIT (Cambridge, MA.). The Hong laboratory develops and applies magic-angle-spinning solid-state NMR spectroscopy to elucidate the structure and dynamics of biological macromolecules. One current research focus of the Hong group is to determine the structure and binding mechanism of a severe acute respiratory syndrome coronavirus 2 (SARS CoV 2) membrane protein.

May 18, 2020 – Cambridge Isotope Laboratories Partners with Alsachim in the Fight Against COVID-19

Through a commercial partnership with Alsachim, Cambridge Isotope Labs (CIL) is proud to now offer an assortment of unlabeled and stable isotope-labeled antiviral drug standards and their metabolites to assist in COVID-19 research and therapy development.

March 17, 2020 – CIL's Response to Coronavirus (COVID-19)

As we continue to monitor and respond to the changing business dynamics created by the Coronavirus (COVID-19), the entire CIL team extends our best wishes to you, your employees and families for good health and peace of mind during a difficult time.

October 29, 2019 – Cliff Caldwell Appointed CEO of CIL

CIL is the world’s largest manufacturer and global supplier of stable isotopes and stable isotope-labeled compounds used in research, environmental, neonatal, pharmaceutical, medical diagnostic, OLED, and industrial markets. CIL is an operating business owned by Otsuka Pharmaceuticals. The CIL business consists of two facilities in the Boston, MA, area; a large isotope-enrichment production plant in Xenia, OH; CIL Canada in Montreal, Canada; CIL China in Shanghai; ABX in Dresden, Germany; and Eurisotop in Saclay, France.

January 23, 2018 – Otsuka Signs Statement of Support for Women’s Empowerment Principles

Cambridge Isotope Laboratories, Inc. (CIL), an indirect subsidiary of Otsuka Holdings Co., Ltd., announces that the latter has signed the CEO Statement of Support for the Women’s Empowerment Principles (WEPs), a set of Principles focusing on corporate action to promote gender equality and women’s empowerment in the workplace, marketplace and community.

October 2, 2017 – Endocyte Announces Exclusive Worldwide License of Phase 3 Ready PSMA-Targeted Radioligand Therapy for Development in Prostate Cancer

West Lafayette, Ind., Oct. 2, 2017 – Endocyte, Inc. (NASDAQ Global Market: ECYT), a biopharmaceutical company developing targeted therapeutics for personalized cancer treatment, today announced the completion of an exclusive worldwide license of PSMA-617 from ABX GmbH. Endocyte intends to move quickly into Phase 3 development of 177Lu-PSMA-617, a radioligand therapeutic (RLT) that targets the prostate-specific membrane antigen (PSMA), present in approximately 80% of patients with metastatic castration-resistant prostate cancer (mCRPC).

April 26, 2017 – In the News – Food and Drug Administration (FDA) Approves the First Deuterated Drug, AUSTEDO™ by Teva

Cambridge Isotope Laboratories, Inc. is pleased that the Food and Drug Administration (FDA) approved the first deuterated drug, AUSTEDO™ by Teva (previously referred to as SD-809).

January 19, 2017 – Cambridge Isotope Laboratories, Inc. is Pleased to Offer Mouse Express® NeuCode™ Mouse Feed

Tewksbury, MA - Cambridge Isotope Laboratories, Inc. (CIL), the world’s leading supplier of stable isotopes and stable isotope-enriched compounds, is pleased to offer Mouse Express® NeuCode™ mouse feed with different combinations of lysine (Lys) isotopologues for 2- and 3-plex, MS proteomic analysis.

October 21, 2016 – Cambridge Isotope Laboratories, Inc. Working with IROA Technologies LLC to Develop and Distribute IROA® Biochemical Quantitation Kits

Tewksbury, MA - Cambridge Isotope Laboratories, Inc. (CIL), the world’s leading supplier of stable isotopes and stable isotope-labeled compounds, is working together with IROA Technologies LLC (IROATECH), a leading developer of novel analytical tools for accurate metabolic analysis, to help develop and distribute IROA® Biochemical Quantitation Kits worldwide for metabolic profiling of various cell populations and biological samples.

May 6, 2016 – CIL Successfully Holds Symposia on Chinese POPs Research Using Isotope Dilution Mass Spectrometry

POPs research is growing rapidly in China, and use of Isotope Dilution MS has been shown to be the most robust method for accurate and precise POPs analysis. Cambridge Isotope Laboratories, Inc. (CIL) is partnered with RCEES,Tongji University and Zhejiang University to hold three symposia for Chinese POPs research using Isotope Dilution Mass Spectrometry. CIL is the global leader in separation of stable isotopes and manufacture of stable isotope-labeled compounds, and wishes to help expand the communication and collaboration of current POPs research in China.

January 31, 2014 – Cambridge Isotope Laboratories and Nexomics Biosciences Sign an Exclusive Worldwide Commercial Supply Agreement

Cambridge Isotope Laboratories, Inc. (CIL), the world’s leading supplier of stable isotopes and stable isotope-enriched small molecules, is working together with Nexomics Biosciences, a structural biology and protein production contract research organization, to provide isotope-labeled proteins to life science research organizations.

August 8, 2008 – Cambridge Isotope Laboratories and CellFree Sciences (CFS) Announce Distribution Agreement

CIL, the world’s leader in the manufacturing of stable isotope-labeled research chemicals, has entered into a distributor agreement with CellFree Sciences Co., Ltd. for the distribution of CFS’s WEPRO Expression Kits and reagents for cell-free protein production for NMR and mass spectrometry applications in North America and Europe. CIL will provide stable isotope-enriched amino acids as a component in the WEPRO Expression Kits.

CIL News| Cambridge Isotope Laboratories
metabolic substrates, isotope labeling, SILAC Amino Acids, protein standards, SILAC, Metabolic Labeling, NMR Tubes, Nucleic Acid Synthesis, alpha keto acids, Cell-Free Protein Expression, deuterated compounds, biomolecular nor, stable isotope, Hyperpolarization, nuclear medicine isotopes, Stable Isotopes, protein NMR, Protein Reagents, Deuterium labeled compounds, minimal media, Heavy Isotopes, metabolic research, custom synthesis, mass spectrometry, list of stable isotopes, Quantitative Proteomics, Nuclear Medicine, Metabolomics, food testing, Solid State NMR, proteomics, Membrane Proteins, mass spectrometry isotopes, Nucleic Acid, NMR, Protein Expression, material testing, Peptide Synthesis
CIL and its people have been committed to high quality stable isotope labeled products, superior customer service, innovative new products and a breadth of product lines.